Table 1.

Response profiles of 19 compounds in a panel of 311 cell lines

CompoundPrimary targetnDescriptive analysis of gIC50 values (nmol/L)
MeanSDQ1MedianQ3MinimumMaximum
pazopanibVEGFR2636,5162,9754,3056,7519,7691610,000
lapatinibERBB1/22686,4313,2614,0317,0469,842110,000
GSK1120212MEK2721,3622,12210492,91105,000
GSK1070916AURKB2711,3212,562211351,157010,000
GSK923295CENPE2703591,537263256610,000
paclitaxelTubulin273149939347010,000
GSK461364PLK1266716556914210,000
GSK661637Pan-PLK2384761,946347110,000
foretinibc-MET2421,1351,4464037331,334010,000
GSK1139710IGF-IR2463,0122,7318862,0904,557110,000
GSK1838705IGF-IR1892,4002,0991,0521,6283,118810,000
GSK1904529IGF-IR1888,3583,59110,00010,00010,0001810,000
PQIPIGF-IR1946,2284,1433,3145,8249,0794420,166
GSK1059615PI3K2401,0378215128321,296465,400
BEZ-235PI3K1962602,0913465140729,326
GSK690693AKT2676,6873,9312,8139,31710,000010,000
perifosineAKT1969,2064,5685,1838,67614,66363814,663
TGX-221PI3K-β19420,8389,89112,76425,75229,3262529,326
temsirolimusmTOR1913,3124,303427515,586220,000

NOTE: Response profiles for all compounds are represented by gIC50 values (nmol/L). Where cells were assayed at multiple plating densities, gIC50s were averaged. Clustering analysis was done with gIC50 scaled by the overall median for each compound to account for differences in potency. Q1 and Q3 represent the 25th and 75th percentiles, respectively, whereas n represents the total number of cell lines assayed for each compound.